U.S. markets close in 5 hours 44 minutes
  • S&P 500

    3,800.01
    -19.71 (-0.52%)
     
  • Dow 30

    31,214.43
    -55.66 (-0.18%)
     
  • Nasdaq

    12,825.67
    -172.08 (-1.32%)
     
  • Russell 2000

    2,188.50
    -19.29 (-0.87%)
     
  • Crude Oil

    62.13
    +0.85 (+1.39%)
     
  • Gold

    1,713.00
    -2.80 (-0.16%)
     
  • Silver

    26.08
    -0.31 (-1.16%)
     
  • EUR/USD

    1.2037
    -0.0031 (-0.25%)
     
  • 10-Yr Bond

    1.4650
    -0.0050 (-0.34%)
     
  • GBP/USD

    1.3977
    +0.0025 (+0.18%)
     
  • USD/JPY

    107.4680
    +0.4660 (+0.44%)
     
  • BTC-USD

    49,205.48
    -1,973.14 (-3.86%)
     
  • CMC Crypto 200

    986.96
    -0.25 (-0.03%)
     
  • FTSE 100

    6,632.38
    -43.09 (-0.65%)
     
  • Nikkei 225

    28,930.11
    -628.99 (-2.13%)
     

Moore Kuehn Encourages CBMG, CLCT, TNAV, and ARA Investors to Contact Law Firm

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Moore Kuehn
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ultimately seek increased consideration, additional disclosures, or other relief and benefits on behalf of the shareholders of these companies:

  • Cellular Biomedicine Group, Inc. (NASDAQ: CBMG)

A proxy was recently filed with the SEC regarding the acquisition of Cellular Biomedicine by a consortium led by the company’s CEO Bizuo Liu. Under the proposed transaction, shareholders of Cellular Biomedicine will receive $19.75 for every share owned. The investigation concerns whether Cellular Biomedicine’s board of directors oversaw an unfair process and ultimately agreed to an inadequate deal price.

  • Collectors Universe, Inc. (NASDAQ: CLCT)

A tender offer expiring on January 19th was commenced by an investor group led by Nat Turner, D1 Capital Partners L.P., and Cohen Private Ventures, LLC to acquire Collectors Universe for $75.25 per share. The solicitation statements filed with the SEC in support of the acquisition may omit material information regarding the financial metrics and analyses used to evaluate the merger.

  • Telenav, Inc. (NASDAQ: TNAV)

A proxy was recently filed with the SEC regarding V99, Inc.’s acquisition of Telenav, which may omit material information regarding the financial metrics and analyses used to evaluate the merger. Under the proposed transaction, shareholders of Telenav will receive $4.80 per share.

  • American Renal Associates Holdings, Inc. (NYSE: ARA)

A proxy was recently filed with the SEC regarding Nautic Partners’ acquisition of American Renal. Under the proposed transaction, shareholders of American Renal will receive $11.50 for every share owned. The investigation concerns whether American Renal’s board of directors oversaw an unfair process and ultimately agreed to an inadequate deal price.

Moore Kuehn is investigating whether the Boards of the above companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process.

Moore Kuehn encourages shareholders who would like to discuss their rights to contact Justin Kuehn, Esq. by email at jkuehn@moorekuehn.com or telephone at (212) 709-8245. The consultation and case are free with no obligation to you. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

Moore Kuehn is a 5-star New York City-based law firm with attorneys representing investors and consumers in class action litigation involving securities law violations, financial fraud, breaches of fiduciary duties, and other claims. For additional information about Moore Kuehn, please go to http://www.moorekuehn.com/practice/new-york-securities-litigation/.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Moore Kuehn, PLLC
Justin Kuehn, Esq.
30 Wall Street, 8th Floor
New York, New York 10005
jkuehn@moorekuehn.com
(212) 709-8245